Document is current
Any future updates will be listed below
-
Authors
Mukhtarzada, Mejgan G.
Monteith, Teshamae S.
- License Information
-
More Information
Article History
Accepted: 15 April 2022
First Online: 14 May 2022
Declarations
:
: Teshamae Monteith has received personal compensation for serving on advisory boards for Biohaven, Allegan/Abbvie, Lundbeck, Amgen, Teva, and Impel Neuropharmaceuticals. She has also served as a site principal investigator without direct compensation for Teva, Eli Lilly, Electrocore, Amgen, and Novartis. Mejgan Mukhtarzada does not report any significant disclosures or conflicts of interest.
: This article does not contain any studies with human or animal subjects performed by the author.
